Human Genome Epidemiology Literature Finder
|
Records 1 - 14 (of 14 Records) |
| Query Trace: Atrial Fibrillation and CYP3A4[original query] |
|---|
| Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. Journal of thrombosis and thrombolysis 2019 Sep . Gulilat Markus, Keller Denise, Linton Bradley, Pananos A Demetri, Lizotte Daniel, Dresser George K, Alfonsi Jeffrey, Tirona Rommel G, Kim Richard B, Schwarz Ute |
| CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Pharmacogenomics and personalized medicine 2020 3 13 29-37. Sychev D A, Baturina O A, Mirzaev K B, Rytkin E, Ivashchenko D V, Andreev D A, Ryzhikova K A, Grishina E A, Bochkov P O, Shevchenko R |
| Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy. Blood 2020 12 137 (20): 2817-2826. Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle |
| MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug metabolism and personalized therapy 2021 8 . Rytkin Eric, Bure Irina V, Bochkov Pavel O, Akmalova Kristina A, Mirzaev Karin B, Cherniaeva Marina S, Ostroumova Olga D, Smirnov Valery V, Grishina Elena A, Saribekian Anna G, Sychev Igor N, Sychev Dmitry |
| MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug metabolism and personalized therapy 2022 4 37 (1): 41-46. Rytkin Eric, Bure Irina V, Bochkov Pavel O, Akmalova Kristina A, Mirzaev Karin B, Cherniaeva Marina S, Ostroumova Olga D, Smirnov Valery V, Grishina Elena A, Saribekian Anna G, Sychev Igor N, Sychev Dmitry |
| Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients. Frontiers in pharmacology 2022 12 13 1007113. Campos-Staffico Alessandra M, Dorsch Michael P, Barnes Geoffrey D, Zhu Hao-Jie, Limdi Nita A, Luzum Jasmine |
| Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. Frontiers in genetics 2022 10 13 982955. Attelind Sofia, Hallberg Pär, Wadelius Mia, Hamberg Anna-Karin, Siegbahn Agneta, Granger Christopher B, Lopes Renato D, Alexander John H, Wallentin Lars, Eriksson Nicl |
| Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. Pharmacogenetics and genomics 2022 Oct . Sychev Dmitry Alekseevitch, Sokolov Aleksey Vladimirovich, Reshetko Olga Vilorovna, Fisenko Vladimir Petrovich, Sychev Igor Nikolaevich, Grishina Elena Anatolievna, Bochkov Pavel Olegovich, Shevchenko Roman Vladimirovich, Abdullaev Sherzod Pardaboevich, Denisenko Natalia Pavlovna, Ivashchenko Dmitry Vladimirovich, Sozaeva Zhannet Alimovna, Kachanova Anastasia Alekseev |
| Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation. Pharmacology 2022 Jan 1-11. Baturina Olga, Andreev Denis, Fedina Ludmila, Mirzaev Karin, Ivashchenko Dmitriy, Ryzhikova Kristina, Grishina Elena, Bochkov Pavel, Shevchenko Roman, Sychev Dmitr |
| Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation. Cardiovascular drugs and therapy 2023 8 . Xiaoye Li, Zhichun Gu, Zi Wang, Qing Xu, Chunlai Ma, Qianzhou |
| ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug design, development and therapy 2023 8 17 2513-2522. Hamin Kim, Tae-Jin Song, Jeong Yee, Dong-Hyeok Kim, Junbeom Park, Hye Sun Gw |
| The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation. Human genomics 2023 7 17 (1): 59. Tingting Wu, Shuyi Wu, Li Li, Jing Xiang, Na Wang, Wenjun Chen, Jinhua Zha |
| The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation. Drug metabolism and personalized therapy 2024 6 . Alena I Skripka, Pavel M Krupenin, Olga N Kozhanova, Anna A Kudryavtseva, Ludmila V Fedina, Kristina A Akmalova, Pavel O Bochkov, Anastasiya A Sokolova, Dmitriy A Napalkov, Dmitriy A Sych |
| Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants. Therapeutic advances in cardiovascular disease 2024 5 18 17539447241249886. Ayan Abdrakhmanov, Aizhana Shaimerdinova, Zhanasyl Suleimen, Svetlana Abildinova, Rustam Albayev, Gulnar Tuyakova, Elena Rib, Akmaral Beysenbayeva, Gulden Kabduyeva, Makhabbat Bekbossyno |
- Page last reviewed:Feb 1, 2024
- Content source: